Just found this Anthrax Market Pipeline Global
Post# of 72447
Posted On: 03/18/2016 10:42:48 AM
Just found this
Anthrax Market Pipeline Global Review Research Report for H2 2015
10:00 pm ET March 17, 2016 (PR Newswire) Print
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Aduro BioTech, Inc., Altimmune, Inc., Aphios Corporation, Aradigm Corporation, Bavarian Nordic A/S, Bristol-Myers Squibb Company, Cellceutix Corporation, ContraFect Corporation, Dynavax Technologies Corporation, ,Elusys Therapeutics, Inc. Emergent BioSolutions Inc., Green Cross Corporation, Grifols, S.A., Hawaii Biotech, Inc., iBio, Inc., Innovative Biologics, Inc., Microbiotix, Inc., NanoBio Corporation, Oragenics, Inc., PaxVax, Pfenex Inc., PharmAthene, Inc., Protein Potential, LLC, ProThera Biologics, LLC., PsiOxus Therapeutics Limited, Soligenix, Inc., Syntiron LLC , Tetraphase Pharmaceuticals Inc., United Therapeutics Corporation and VLP Biotech, Inc.
Complete report on H2 2015 pipeline review of Anthrax with 53 market data tables and 15 figures, spread across 160 pages is available at http://www.reportsnreports.com/reports/432806...-2015.html
Drugs Profiles discussed in this report includes anthrax + plague vaccine, anthrax vaccine - Drug Profile, anthrax vaccine next generation, anthrax virus like particle vaccine, ARD-3100, AV-7909, CF-306, CF-307, CF-308, ciprofloxacin hydrochloride, DPX-Anthrax, DV-230, Epimerox, GC-1109, GREANX, Human Antibody Based Vaccines, KKL-35, Marinus, MDX-1303, Monoclonal Antibody for Respiratory Anthrax, Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax, MU-1140, MVA-BN Anthrax, obiltoxaximab, PBI-220, Peptides to Disrupt Cell Membrane for Infectious Diseases, PMX-0196, PMX-0231, PMX-0243, PMX-225, PreviThrax, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, Px-563L, RC-100b, RiVax + SGX-204, Second Generation Px-563L, SGX-204, Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia, Small Molecule to Inhibit DNA Helicase for Infectious Diseases, Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections, Small Molecules for Bacterial Infections, Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis, Synthetic Peptides for Bacterial Infections and TP-271.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=432806 (This is a premium report priced at US$2000 for a single user License.)
Anthrax Market Pipeline Global Review Research Report for H2 2015
10:00 pm ET March 17, 2016 (PR Newswire) Print
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Aduro BioTech, Inc., Altimmune, Inc., Aphios Corporation, Aradigm Corporation, Bavarian Nordic A/S, Bristol-Myers Squibb Company, Cellceutix Corporation, ContraFect Corporation, Dynavax Technologies Corporation, ,Elusys Therapeutics, Inc. Emergent BioSolutions Inc., Green Cross Corporation, Grifols, S.A., Hawaii Biotech, Inc., iBio, Inc., Innovative Biologics, Inc., Microbiotix, Inc., NanoBio Corporation, Oragenics, Inc., PaxVax, Pfenex Inc., PharmAthene, Inc., Protein Potential, LLC, ProThera Biologics, LLC., PsiOxus Therapeutics Limited, Soligenix, Inc., Syntiron LLC , Tetraphase Pharmaceuticals Inc., United Therapeutics Corporation and VLP Biotech, Inc.
Complete report on H2 2015 pipeline review of Anthrax with 53 market data tables and 15 figures, spread across 160 pages is available at http://www.reportsnreports.com/reports/432806...-2015.html
Drugs Profiles discussed in this report includes anthrax + plague vaccine, anthrax vaccine - Drug Profile, anthrax vaccine next generation, anthrax virus like particle vaccine, ARD-3100, AV-7909, CF-306, CF-307, CF-308, ciprofloxacin hydrochloride, DPX-Anthrax, DV-230, Epimerox, GC-1109, GREANX, Human Antibody Based Vaccines, KKL-35, Marinus, MDX-1303, Monoclonal Antibody for Respiratory Anthrax, Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax, MU-1140, MVA-BN Anthrax, obiltoxaximab, PBI-220, Peptides to Disrupt Cell Membrane for Infectious Diseases, PMX-0196, PMX-0231, PMX-0243, PMX-225, PreviThrax, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, Px-563L, RC-100b, RiVax + SGX-204, Second Generation Px-563L, SGX-204, Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia, Small Molecule to Inhibit DNA Helicase for Infectious Diseases, Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections, Small Molecules for Bacterial Infections, Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis, Synthetic Peptides for Bacterial Infections and TP-271.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=432806 (This is a premium report priced at US$2000 for a single user License.)
(0)
(0)